随着创新药行情爆发，信达生物年初至今涨幅已超150%，市值超1600亿港元。重仓信达生物、百济神州等标的的恒生生物科技指数年内涨幅超80%，在全市场指数中涨幅靠前。在跟踪恒生生物科技指数的ETF中，恒生医药ETF以超60亿的规模位列同类第一；该指数的期货也将于11月28日于港交所上市交易，为投资者提供新的风险对冲工具。消息面来看，恒生指数公司近期公布了其定期的季度指数调整结果，信达生物将被纳入...
Source Link随着创新药行情爆发，信达生物年初至今涨幅已超150%，市值超1600亿港元。重仓信达生物、百济神州等标的的恒生生物科技指数年内涨幅超80%，在全市场指数中涨幅靠前。在跟踪恒生生物科技指数的ETF中，恒生医药ETF以超60亿的规模位列同类第一；该指数的期货也将于11月28日于港交所上市交易，为投资者提供新的风险对冲工具。消息面来看，恒生指数公司近期公布了其定期的季度指数调整结果，信达生物将被纳入...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.